Q&A: AstraZeneca Execs Talk Immunotherapy Strategy And More At ASCO
Chief Medical Officer Briggs Morrison and Senior VP for Oncology Global Portfolio and Product Strategy Mondher Mahjoubi sat down with “The Pink Sheet” to discuss the firm’s oncology strategy and outlook, including the choices it’s making with immuno-oncology, the valuation of the oncology franchise and the climate for cancer drug prices.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.